Učitavanje...
CLINICAL AND THERAPEUTIC IMPLICATIONS OF SPROUTY2 FEEDBACK DYSREGULATION IN BRAF V600E MUTATION POSITIVE PAPILLARY THYROID CANCER
BACKGROUND: The BRAF V600E (BRAF+) mutation activates the MAPK/ERK pathway and may confer an aggressive phenotype in papillary thyroid cancer (PTC). However, clinically BRAF+PTC behavior varies from indolent to aggressive. SPRY2 is a negative feedback regulator of the MAPK/ERK pathway. We hypothesiz...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2013
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4100696/ https://ncbi.nlm.nih.gov/pubmed/24094449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.surg.2013.06.024 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|